Geron (GERN) Receives News Impact Rating of 0.16
News coverage about Geron (NASDAQ:GERN) has been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Geron earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.9658726588266 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Why Geron Corporation Stock Is Rising Today (finance.yahoo.com)
- Investors must not feel shy to buy these stocks: Geron Corporation, (NASDAQ: GERN), Abercrombie & Fitch Co., (NYSE … – StocksNewsPro (press release) (stocksnewspro.com)
- Geron (GERN) Upgraded at BidaskClub (americanbankingnews.com)
- Geron Corporation (GERN) Is It Worthy for Investors? – ExpertGazette (expertgazette.com)
- Geron (GERN) Set to Announce Quarterly Earnings on Friday (americanbankingnews.com)
Geron (NASDAQ:GERN) opened at $2.98 on Wednesday. The company has a market capitalization of $474.51, a PE ratio of -16.56 and a beta of 2.77. Geron has a twelve month low of $1.74 and a twelve month high of $3.24.
WARNING: “Geron (GERN) Receives News Impact Rating of 0.16” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/03/14/geron-gern-receives-news-impact-rating-of-0-16.html.
Geron Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.